Woodline Partners Adds $53M in Quest Diagnostics Incorporated ($DGX)
Key Points
- Woodline Partners changed its Quest Diagnostics Incorporated ($DGX) stake by 73.93% last quarter, boosting to 593,744 shares worth $125.84 million.
- $DGX last traded around $211.95.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Woodline Partners increased its position in Quest Diagnostics Incorporated ($DGX) by 73.93% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 593,744 shares of Quest Diagnostics Incorporated after buying 252,372 shares during the quarter. Woodline Partners's holdings in Quest Diagnostics Incorporated were worth $125.84 million as of its most recent filing.
Quest Diagnostics Incorporated Stock Down 12.7%
Shares of Quest Diagnostics Incorporated ($DGX) traded around $211.95 on Saturday, down 12.7% for the day.
Quest Diagnostics Incorporated Earnings
Quest Diagnostics Incorporated Dividend
Analysts Set New Price Targets
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Get Quest Diagnostics Incorporated alerts
New 13F filings, insider trades, and analyst moves on $DGX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.